Excrement treatment apparatus and adsorption column
The excrement treatment apparatus addresses the lack of radioactive substance removal in radiopharmaceutical facilities by using an adsorption column with ultraviolet irradiation and transport paths to safely process and dispose of excrement, minimizing exposure and environmental impact.
Patent Information
- Application Number
- PCT/JP2026/016614
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-08-27
- Filing Date
- 2026-04-27
- Publication Date
- 2026-11-12
AI Technical Summary
Existing radiopharmaceutical administration facilities lack a mechanism to effectively remove radioactive substances from patient excrement, posing risks of exposure to medical personnel and environmental contamination.
An excrement treatment apparatus comprising a first container, an adsorption column, a pre-column transport path with ultraviolet irradiation, and a post-column transport path, which includes a tube pump to process and dispose of excrement, ensuring removal of radioactive substances.
The apparatus efficiently removes radioactive materials from excrement, reducing the risk of exposure and environmental contamination, allowing safe administration of radiopharmaceuticals without overburdening wastewater treatment systems.
Smart Images

Figure JP2026016614_12112026_PF_FP_ABST
Abstract
Description
Excrement Treatment Apparatus and Adsorption Column
[0001] The present invention relates to an excrement treatment apparatus and an adsorption column.
[0002] A radiopharmaceutical administration facility has been proposed in which administration of a radiopharmaceutical and waiting for the components of the radiopharmaceutical to distribute throughout the patient's body are performed at the same location (Patent Document 1).
[0003] Japanese Unexamined Patent Application Publication No. 2023-140710
[0004] The excrement of a patient administered a radiopharmaceutical contains radioactive substances that are nuclides derived from the radiopharmaceutical. However, the administration facility of Patent Document 1 does not include a mechanism for appropriately removing the radioactive substances contained in the excrement.
[0005] In one aspect, an object is to provide an excrement treatment apparatus and the like that removes radioactive substances contained in the excrement of a patient administered a radiopharmaceutical.
[0006] The excrement treatment apparatus includes a first container that stores excrement of a patient administered a radiopharmaceutical, an adsorption column that adsorbs radioactive substances contained in the excrement, a pre-column transport path that transports the excrement from the first container to the adsorption column, an ultraviolet lamp that irradiates the pre-column transport path with ultraviolet light, a post-column transport path that transports the excrement from the adsorption column to a second container, and a tube pump disposed in the middle of the post-column transport path.
[0007] In one aspect, the excrement treatment apparatus that removes radioactive substances contained in the excrement of a patient administered a radiopharmaceutical can be provided.
[0008] This is an explanatory diagram illustrating the outline of a waste disposal method. This is an explanatory diagram illustrating the configuration of a waste disposal device. This is an explanatory diagram illustrating the waste disposal procedure. This is a perspective view of an adsorption column. This is a half-sectional view of an adsorption column. This is a half-sectional view of the adsorption column of Embodiment 2. This is a half-sectional view of the adsorption column of Embodiment 3. This is a graph showing the relationship between the liquid flow rate and flow velocity of the adsorption column of Embodiment 3. This is a half-sectional view of an adsorption column of a modified example. This is an explanatory diagram illustrating the configuration of a waste disposal device of Embodiment 4. This is an explanatory diagram illustrating the configuration of a waste disposal device of Modified Example 4-1. This is a cross-sectional view of a pre-filter unit. This is an explanatory diagram illustrating the configuration of a waste disposal device of Modified Example 4-2. This is an explanatory diagram illustrating the configuration of a waste disposal device of Embodiment 5.
[0009] [Embodiment 1] A radiopharmaceutical is used in which a substance that easily accumulates in target cells such as tumor cells is labeled with a radionuclide. The target cells are damaged by the radiation emitted by the radionuclide that has accumulated in the target cells.
[0010] The following explanation uses Lutatera®, a radiopharmaceutical used in peptide receptor radionuclide therapy (PRRT), a treatment for neuroendocrine tumors (NETs), a type of rare cancer, as an example. The generic name for Lutatera is lutetium oxodotreotide (177Lu).
[0011] It is known that somatostatin receptors are expressed on the surface of neuroendocrine tumor cells with a high probability. In PRRT, Lutatera, a radiopharmaceutical labeled with the radionuclide 177Lu (lutetium-177) to contain a peptide that binds to somatostatin receptors and is taken up by neuroendocrine tumor cells, is administered to the patient by intravenous infusion. The radiopharmaceutical circulates throughout the patient's body via the bloodstream and is eventually taken up by neuroendocrine tumor cells. The beta and gamma rays emitted by 177Lu damage the neuroendocrine tumor cells, causing necrosis. Neuroendocrine tumors are treated through this process.
[0012] Incidentally, in the process of producing 177Lu by irradiating 176Lu (lutetium-176) with neutron beams, the heteronuclide 177m-Lu is also produced. According to the interview form issued regarding Lutatera intravenous injection, the contamination rate of 177m-Lu to 177Lu is less than 0.05 percent.
[0013] Radiopharmaceuticals that are not taken up by neuroendocrine tumor cells are metabolized in the patient's body over time and excreted mainly in the urine. Therefore, the patient's urine contains 177Lu, which has a physical half-life of 6.647 days, in addition to a small amount of 177m-Lu, which has a physical half-life of 160.4 days.
[0014] The presence of 177 m-Lu is ignored in wastewater standards such as guidelines. If the number of cases using Rutatera increases in the future, there are concerns about exposure to patients and medical personnel in rooms using radioactive isotopes for medical treatment, radiation therapy rooms and special treatment rooms, as well as residual radioactivity after discharge into RI (radioisotope) wastewater tanks and sewage. Therefore, it is desirable to implement a system to appropriately recover radioactive materials from urine.
[0015] When medical institutions discharge so-called radioactive wastewater containing radioactive materials such as 177Lu, they must wait for the radiation levels to decrease to the values specified in the aforementioned wastewater standards, or dilute the wastewater to reduce the radiation levels, before discharging it into the sewer system. By properly recovering radioactive materials contained in patients' urine and preventing their release into the wastewater treatment system installed within the medical institution, physicians can use Lutatera on patients who need it without considering the load on the wastewater treatment system.
[0016] Figure 1 is an explanatory diagram illustrating the general outline of the waste disposal method. First, let's describe the patient. The patient receiving radiation therapy in this embodiment is a patient whose somatostatin receptor has been confirmed to be expressed in the tumor through prior examination.
[0017] To prevent exposure of medical personnel to radiation, patients are isolated in radiation therapy rooms or special treatment rooms. Radiopharmaceuticals are administered intravenously to patients in these rooms. After administration, the amount of radiation emitted from the body is measured periodically, and discharge is permitted only after it is confirmed to be below the standard. Hospital stays are typically one to two days.
[0018] This completes one dose of the radiopharmaceutical. After discharge, the emission of beta and gamma rays from 177Lu taken up by neuroendocrine tumor cells continues, and treatment for the neuroendocrine tumor continues. The radiopharmaceutical is administered a total of four times, at eight-week intervals, as a general rule.
[0019] The excrement of the patient in isolation is collected in the first container 31. Since the radioactive material contained in Rutatera is mainly excreted in the urine, only the urine from the excrement may be collected in the first container 31. Therefore, the first container 31 is, for example, a urine collection container. It is desirable that the first container 31 be covered with a radiation shielding material such as lead or tungsten.
[0020] If solid materials such as toilet paper contaminated with feces and excrement are also contained in the first container 31, it is desirable that the first container 31 be equipped with a mechanism, such as a magnetic stirrer, to agitate the contents and liquefy the entire contents. By containing the solid materials in the first container 31 and performing the processing described later, the risk of radioactive contamination from untreated radioactive materials can be reduced. For example, deodorizers, preservatives, or disinfectants may be added to the first container 31.
[0021] As mentioned above, the amount of radiation emitted from the body of patients in isolation is measured, and they are permitted to be discharged only after it is confirmed that the levels are below the standard. The excrement contained in the first container 31 is collected periodically or after the patient is discharged.
[0022] For excrement, ultraviolet irradiation is first performed, followed by the adsorption of radioactive materials using an adsorption column 41. The adsorption column 41, having adsorbed the radioactive materials, is then handed over to a radioactive waste disposal company. In Japan, the processing of medical radioactive waste is effectively monopolized by JRIA (Japan Radioisotope Association).
[0023] The excrement that has passed through the adsorption column 41 is collected in the second container 32. The contents of the second container 32 are tested for radiation levels. After it is confirmed that the radiation levels are below the wastewater standards, the contents of the second container 32 are disposed of in the sewer system. If the radiation levels are not below the wastewater standards, additional treatments are taken, such as waiting until the radioactive dose decreases due to radioactive decay, repeating the treatment with the adsorption column 41, or diluting the excrement.
[0024] If it is necessary to wait for the radioactive dose to decrease due to radioactive decay, the second container 32 is stored in a warehouse or similar location. For example, the storage period until the radiation dose falls below the wastewater standard may be calculated based on the radiation dose and the half-life of the radioactive nuclide. The contents of the second container 32, once the radiation dose has not fallen below the wastewater standard, may be poured into other storage tanks for radioactive liquid waste managed by the medical institution.
[0025] The reasons why ultraviolet irradiation is necessary are explained below. Waste discharged from medical institutions such as hospitals, clinics, and nursing homes that may contain pathogens that can infect humans, or pathogens that may potentially infect humans, is called infectious waste. Medical institutions have an obligation to separate infectious waste from other waste and dispose of it appropriately. Many medical institutions outsource the disposal of infectious waste to infectious waste disposal companies.
[0026] The excrement of patients, such as feces and urine, is not usually treated as infectious waste. In medical facilities, the excrement of infectious disease patients is flushed down the toilet just like the excrement of healthy people. This is because common infectious disease pathogens can be safely treated in normal sewage treatment facilities.
[0027] According to the "Guidelines on the Proper Disposal of Infectious Waste" issued by the Ministry of the Environment in March 2004, the excrement of patients with four Category I infectious diseases, including Ebola hemorrhagic fever and Marburg disease, requires strict disinfection. However, it is unlikely that patients suffering from these Category I infectious diseases would be administered radiopharmaceuticals in parallel with treatment for their infectious diseases. Therefore, in the following explanation, the excrement of patients with these Category I infectious diseases will be excluded from consideration.
[0028] The same notification stipulates that disposable diapers used by patients suffering from certain diseases, such as hepatitis E, hepatitis A, rubella, varicella, syphilis, methicillin-resistant Staphylococcus aureus infection, and drug-resistant Pseudomonas aeruginosa infection, are considered infectious waste. The same applies to disposable diapers used by patients with designated infectious diseases and newly emerging infectious diseases. However, there are no specific regulations regarding the excrement itself of these infectious disease patients. Therefore, these infectious disease patients can use toilets as usual.
[0029] In other words, in the case of patients suffering from certain infectious diseases, excrement that adheres to diapers and cannot be flushed down the toilet needs to be separated and disposed of as infectious waste. Therefore, it is considered that the adsorption column 41 used to process the excrement of these patients also needs to be disposed of as infectious waste, just like the diapers.
[0030] Among the diseases listed in the aforementioned notification, syphilis, methicillin-resistant Staphylococcus aureus infection, and drug-resistant Pseudomonas aeruginosa infection can become chronic. For patients whose symptoms have subsided while remaining chronic, radiopharmaceuticals may be administered. The adsorption column 41 used to remove radioactive materials from the excrement of such patients is both radioactive waste and infectious waste.
[0031] However, the Japan Isotope Association requires that radioactive waste that may pose an infection risk be sterilized before being handed over. The adsorbent used in the adsorption column 41 has many pores and other structures to increase its specific surface area. It is difficult to sterilize the adsorption column 41 when radioactive materials and pathogens are mixed and clogged in these pores and structures.
[0032] Therefore, in this embodiment, the excrement contained in the first container 31 is first irradiated with ultraviolet light to reduce the number of pathogens in the excrement to a level that can suppress the transmission of infectious diseases. The intensity of the ultraviolet light and the irradiation time are predetermined to ensure that a sufficient ultraviolet disinfection effect is obtained.
[0033] By passing the excrement, after UV disinfection, through the adsorption column 41, radioactive materials are adsorbed onto the adsorption column 41. Since the adsorption column 41 does not need to be handled as infectious waste, sterilization is not required.
[0034] Figure 2 is an explanatory diagram illustrating the configuration of the excrement processing device 30. The excrement processing device 30 comprises a first container 31, a second container 32, a third container 33, an ultraviolet lamp 51, an adsorption column 41, a pump 56, a first valve 61, a second valve 62, and a housing 38. The ultraviolet lamp 51 has a rod-shaped light-emitting part 52. The light-emitting part 52 emits ultraviolet light in the UV-C band used for ultraviolet disinfection.
[0035] The light-emitting part 52 is inserted through the center of the spiral tube 58. The spiral tube 58 is a tube made of a material with high transmittance of ultraviolet light in the UV-C band, and is formed in a spiral shape. The spiral tube 58 is made of, for example, synthetic quartz glass, natural quartz glass, or ultraviolet-transmitting glass. In the following description, the length of the spiral tube 58 means the length when the spiral tube 58 is straightened out, and the diameter of the spiral tube 58 means the diameter of the spirally formed tube itself.
[0036] Pump 56 is a tube pump that pumps liquid through a flexible tube by pressing it against a roller. Since the tube pump does not come into contact with the liquid being pumped, it is not contaminated by radioactive materials and pathogens contained in excrement. The first valve 61 and the second valve 62 each have three connection ports.
[0037] The housing 38 is an exterior component of the waste disposal device 30. The housing 38 is preferably made of lead or tungsten and has a radiation shielding function. The housing 38 is equipped with a door that can be opened and closed by the user, allowing the user to replace the internal container and tubes as needed. The housing 38 may also be a box-type housing that the user places over the container and tubes after they have been properly arranged.
[0038] The waste disposal device 30 is equipped with a vacuum pump that maintains a negative pressure inside the housing 38 compared to the outside air, and a HEPA (High Efficiency Particulate Air) filter may be placed at the exhaust port. Maintaining a negative pressure inside the housing 38 prevents the scattering of radioactive materials to the outside of the housing 38.
[0039] As mentioned above, the first container 31 contains the patient's excrement. The excrement of multiple patients may be contained in one first container 31. Similarly, the second container 32 contains the excrement after ultraviolet irradiation and radionuclide removal. The third container 33 contains a disinfectant.
[0040] A sixth tube 26, with one end positioned near the bottom, is inserted into the third container 33. The other end of the sixth tube 26 is connected to the connection port of the first valve 61. The lid of the third container 33 and the insertion port of the sixth tube 26 are not airtight, allowing air to flow into the third container 33 through the gaps.
[0041] A seventh tube 27 with one end disposed near the bottom is inserted into the first container 31. The other end of the seventh tube 27 is connected to the connection port of the second valve 62. The lid of the first container 31 and the insertion port of the seventh tube 27 do not have airtightness, and air can flow into the first container 31 through the gap.
[0042] The first container 31 may be provided with a check valve that permits air to pass when the inside of the first container 31 is under negative pressure, and blocks air passage when the inside of the first container 31 is under positive pressure. By providing the check valve, it is possible to prevent radioactive substances, pathogens and the like inside the first container 31 from scattering into the excreta treatment apparatus 30.
[0043] A third tube 23 is connected between the first valve 61 and the second valve 62. A fourth tube 24 with one end open is connected to the first valve 61. The first valve 61 switches the communication destination of the third tube 23 between the fourth tube 24 and the sixth tube 26.
[0044] A first tube 21 is connected between the second valve 62 and one end of the spiral tube 58. The second valve 62 switches the communication destination of the first tube 21 between the third tube 23 and the seventh tube 27. The light emitting unit 52 and the spiral tube 58 are covered with a light shielding body 53.
[0045] The light shielding body 53 functions to protect other components constituting the excreta treatment apparatus 30 from deterioration caused by ultraviolet rays emitted by the ultraviolet lamp 51. In the case of a structure that allows the door or the like of the housing 38 to be opened while the ultraviolet lamp 51 is lit, the light shielding body 53 also functions to protect the user who opens the door or the like of the housing 38 from exposure to ultraviolet rays.
[0046] The inner surface of the light shielding body 53 is preferably an ultraviolet reflecting surface that favorably reflects ultraviolet light in the UV-C band. For example, the light shielding body 53 is preferably entirely or at its inner surface made of aluminum, which is known to have high reflectance for ultraviolet light in the UV-C band. By reflecting the ultraviolet rays emitted from the light emitting part 52 on the inner surface of the light shielding body 53, both the inner side and the outer side of the spiral tube 58 are irradiated with the ultraviolet rays. Therefore, the liquid flowing inside the spiral tube 58 is efficiently irradiated with the ultraviolet rays.
[0047] The second tube 22 is connected between the other end of the spiral tube 58 and the inflow port of the adsorption column 41. The seventh tube 27, the first tube 21, the spiral tube 58 and the second tube 22 constitute a pre-column transport path that transports excrement from the first container 31 to the adsorption column 41.
[0048] A flexible fifth tube 25 is connected between the outflow port of the adsorption column 41 and the second container 32. The fifth tube 25 functions as a post-column transport path that transports excrement from the adsorption column 41 to the second container 32. A midway portion of the fifth tube 25 is sandwiched by the rollers of the pump 56. The insertion ports of the second container 32 and the fifth tube 25 do not have airtightness, and the state is set such that the air inside the second container 32 can flow out through the gap.
[0049] The operation of the excrement processing apparatus 30 will be described. In the following description, the first valve 61, the second valve 62, the ultraviolet lamp 51 and the pump 56 are each controlled by, for example, a sequence control circuit (not shown) or a PID (Proportional-Integral-Derivative Controller) control circuit or the like.
[0050] A control unit of a computer (not shown) may control the first valve 61, the second valve 62, the ultraviolet lamp 51 and the pump 56 based on a program. An operator of the excrement processing apparatus 30 may appropriately operate the first valve 61, the second valve 62, the ultraviolet lamp 51 and the pump 56.
[0051] Figure 3 is an explanatory diagram illustrating the waste disposal procedure. All or part of the user tasks described below may be performed by an autonomous or remotely controlled robot. Using a robot can reduce the risk of user exposure and infection.
[0052] First, the preparation stage will be described. The user places the first container 31 containing the excrement in the designated position and attaches the seventh tube 27. The user places the second container 32, which is empty or has sufficient free space, in the designated position and attaches the fifth tube 25. The user places the third container 33 containing the disinfectant in the designated position and attaches the sixth tube 26. The user places the new adsorption column 41 in the designated position.
[0053] The user connects the third tube 23, the fourth tube 24, and the sixth tube 26 to the first valve 61, setting the fourth tube 24 and the third tube 23 to be in communication. In other words, at the stage when the excrement processing device 30 starts operation, the sixth tube 26 and the third tube 23 are not in communication.
[0054] The user connects the first tube 21, the third tube 23, and the seventh tube 27 to the second valve 62, setting the first tube 21 and the seventh tube 27 to communicate. In other words, at the stage when the excrement processing device 30 starts operation, the first tube 21 and the third tube 23 are not communicating.
[0055] The user connects the first tube 21 to the spiral tube 58. The user connects the second tube 22 between the spiral tube 58 and the inlet of the adsorption column 41. The user connects the fifth tube 25 between the outlet of the adsorption column 41 and the second container 32. The user clamps the fifth tube 25 into the roller of the pump 56.
[0056] The user places the light-shielding body 53 over the light-emitting unit 52 and then closes the housing 38. This completes the preparation stage. The user then starts the operation of the waste disposal device 30, for example, by operating the start switch. Subsequent processing is performed automatically by a sequence control circuit or the like, or by the user manually operating switches provided individually on the first valve 61, the second valve 62, the ultraviolet lamp 51, and the pump 56.
[0057] The ultraviolet lamp 51 is turned on, and ultraviolet light is irradiated onto the spiral tube 58 from the light-emitting unit 52. The pump 56 operates, transferring the contents of the fifth tube 25 from the adsorption column 41 side to the second container 32 side. Negative pressure is applied to the adsorption column 41, the second tube 22, the spiral tube 58, the first tube 21, and the seventh tube 27, drawing the excrement contained in the first container 31 into the seventh tube 27.
[0058] The processing that the excrement undergoes while moving from the first container 31 to the second container 32 will now be described. The excrement flows from the seventh tube 27 through the second valve 62 and the first tube 21 into the spiral tube 58. The excrement is disinfected by ultraviolet light emitted from the light-emitting unit 52.
[0059] The duration of ultraviolet irradiation is determined by a combination of the length of the spiral tube 58 and the fluid delivery speed of the pump 56. The intensity of ultraviolet light irradiated onto the excrement is determined by a combination of the diameter of the spiral tube 58 and the intensity of ultraviolet light emitted from the light-emitting section 52. The excrement treatment device 30 is configured to ensure that ultraviolet irradiation of appropriate intensity and duration is performed, thereby obtaining a sufficient ultraviolet disinfection effect.
[0060] Specifically, the user can adjust the pumping rate of the pump 56 to an optimal value based on the type of radiopharmaceutical administered to the patient, the expected radioactive metabolites, the drugs and fluids administered concomitantly at the time of administration, and the patient's renal function. By adjusting the pumping rate of the pump 56 to an optimal value, the user can maximize the removal rate of radioactive material from the patient's excretions.
[0061] After UV disinfection, the excrement flows into the adsorption column 41, and radioactive materials are adsorbed onto the adsorbent packed in the adsorption column 41. Details of the adsorption column 41 will be described later. After passing through the adsorption column 41, the excrement from which the radioactive materials have been removed flows into the second container 32.
[0062] After the processing of the excrement contained in the first container 31 is completed, the first valve 61 and the second valve 62 are switched to open the sixth tube 26 and the third tube 23, and the third tube 23 and the first tube 21.
[0063] The disinfectant in the third container 33 is drawn up into the sixth tube 26, flushing out the first tube 21, the spiral tube 58, the adsorption column 41, and the fifth tube 25. After the third container 33 is empty, the first valve 61 is switched on, connecting the fourth tube 24 and the third tube 23. The disinfectant remaining in the third tube 23, the first tube 21, the spiral tube 58, the second tube 22, the adsorption column 41, and the fifth tube 25 is pushed out by the air drawn in from the tip of the fourth tube 24 and flows into the second container 32.
[0064] The user opens the housing 38 and removes each tube. The user collects each container and tube, etc. The user moves the adsorption column 41 to the designated storage location as radioactive waste and hands it over to a radioactive waste disposal company at a later date. The user inspects the radiation level of the second container 32 as described above, and if it is below the standard, the user puts the contents into the sewage system. The user inspects and cleans the spiral tube 58, the first valve 61, and the second valve 62 in preparation for the next use.
[0065] The user may treat the first container 31, the second container 32, the third container 33, and each tube as single-use materials and discard them, or they may inspect and clean them and reuse them. The decision of which to do is to be made based on a comparison of the cost of purchasing new materials versus the cost of inspection and cleaning.
[0066] Figure 4 is a perspective view of the adsorption column 41. Figure 5 is a half-cross-sectional view of the adsorption column 41. The adsorption column 41 comprises a column tube 42, two column caps 43, two frits 45, and an adsorbent 46.
[0067] The column cylinder 42 is substantially cylindrical in shape and has a narrow-diameter section 421 in the center of its longitudinal direction, which is narrower than the rest of the cylinder. Flat sections 422 are formed on both sides of the narrow-diameter section 421. The manufacturing year of the column cylinder 42 is displayed on one flat section, and the manufacturing month of the column cylinder 42 is displayed on the other flat section. The lot number of the column cylinder 42 may also be displayed on the flat sections 422.
[0068] Disc-shaped frits 45 are fitted into both end faces of the column cylinder 42. The region surrounded by the two frits 45 and the column cylinder 42 is filled with an adsorbent 46. The adsorbent 46 is a material that readily adsorbs radioactive substances contained in radiopharmaceuticals administered to patients. Details of the adsorbent 46 will be described later.
[0069] The frit 45 has numerous pores that are sized to allow liquid to pass through but not the adsorbent 46. The frit 45 prevents the adsorbent 46 from flowing out of the adsorption column 41 and uniformly disperses the liquid that flows into the adsorption column 41 from the inlet inside the column cylinder 42.
[0070] Column caps 43 are attached to both ends of the adsorption column 41. The column caps 43 have a tube mounting port 431 and a lid portion 432. The lid portion 432 is roughly cup-shaped and covers the ends of the column cylinder 42 from the outside. A small-diameter tube mounting port 431 protrudes from the bottom of the lid portion 432. The tube mounting port 431 is sized and shaped so that the second tube 22 and the fifth tube 25 can be inserted and secured.
[0071] The column cylinder 42 may be cylindrical with any cross-sectional shape, such as a roughly rectangular or roughly elliptical shape. Regardless of the shape, a frit 45 is used that seals the inner surface of the column cylinder 42.
[0072] The outer surface of the tube mounting port 431 may be provided with a lip or rib to prevent the tube from coming off. The tube mounting port 431 may also be provided with a one-touch fitting such as a push-in fitting.
[0073] In the case of an adsorption column 41 with a distinguished inlet side and outlet side, it is preferable that the inlet side lid 432 and the outlet side lid 432 have different shapes or colors so that they can be clearly distinguished. For example, by using tubes of different diameters for the second tube 22 and the fifth tube 25, and using a column lid 43 having a tube mounting port 431 suitable for the diameter of each tube, misconnection of the adsorption column 41 can be prevented.
[0074] The inner surface of the lid portion 432 is provided with two stepped sections, the inner diameter of which decreases toward the tube mounting port 431 side. The end face of the column cylinder 42 abuts against the step closest to the opening side of the lid portion 432.
[0075] The column tube 42 and column lid 43 are made of a resin such as polyethylene, polypropylene, or polytetrafluoroethylene, and are manufactured by injection molding.
[0076] The effect of the narrow-diameter section 421 will now be explained. Because the central part of the adsorption column 41 is narrow, it is easy to grasp when carrying it and when installing it inside the waste treatment device 30, and it is less likely to be dropped. The fluid flowing inside the column cylinder 42 is constricted at the narrow-diameter section 421 and then expands, causing agitation. As a result, it is less likely that there will be a section along the inner surface of the column cylinder 42 that passes without hardly touching the adsorbent 46, that is, a section in which radioactive material flows out without sufficient contact with the adsorbent 46. Thus, an adsorption column 41 that can properly remove radioactive material can be provided.
[0077] Table 1 shows examples of adsorbents 46. Multiple types of adsorbents 46 may be mixed and used together.
[0078]
[0079] The cross-section of the tube constituting the spiral tube 58 may be oval or elliptical, etc. By using a spiral tube 58 formed with its long axis oriented in the longitudinal direction of the light-emitting unit 52, the excrement flowing inside the spiral tube 58 can be efficiently disinfected with ultraviolet light. The user may select a spiral tube 58 of appropriate length and diameter depending on the type of infectious disease the patient is suffering from.
[0080] The spiral tube 58 may be made of a resin with relatively high transmittance of UV-C ultraviolet light, such as polyethylene or polyvinyl alcohol. For example, quartz glass with a thickness of 2.5 millimeters transmits about 90 percent of UV-C ultraviolet light, while polyethylene with a thickness of 0.4 millimeters transmits about 60 to 70 percent of UV-C ultraviolet light.
[0081] Therefore, when resin is used as the material for the spiral tube 58, the user forms the spiral tube 58 by using a tube with the thinnest possible wall thickness and winding it spirally around the light-emitting part 52. The first tube 21, the spiral tube 58, and the second tube 22 may be made up of a single continuous tube. This single continuous tube and the seventh tube 27 form the pre-column transport path.
[0082] Compared to quartz, it has a lower transmittance of UV-C ultraviolet light, so it is necessary to use a UV lamp 51 with high emission intensity or to extend the processing time. However, because it is significantly cheaper than quartz, it is possible to realize a spiral tube 58 that can be disposed of after a single use.
[0083] Parameters that affect the effectiveness of ultraviolet disinfection, such as the intensity of ultraviolet light emitted by the ultraviolet lamp 51 or the liquid delivery speed of the pump 56, may be set automatically or appropriately by user operation depending on the type of infectious disease the patient has.
[0084] Instead of the ultraviolet lamp 51, a gamma ray sterilizer or an electron beam sterilizer may be used, for example. Instead of arranging the spiral tube 58 on the outside of the light-emitting section 52, a waterproof ultraviolet lamp 51 may be placed inside a cylindrical tube.
[0085] According to this embodiment, a waste disposal device 30 can be provided that removes radioactive substances contained in the excrement of patients who have received radiopharmaceuticals by adsorbing them onto an adsorption column 41. By disinfecting the excrement with ultraviolet light before passing it through the adsorption column 41, the waste disposal device 30 can be provided that allows the adsorption column 41 to be handed over to a radioactive waste disposal company.
[0086] By using the waste disposal device 30 of this embodiment, the amount of radioactive material released from medical institutions into the sewer system can be reduced. Therefore, physicians can appropriately administer treatment using radiopharmaceuticals to patients who need it without having to consider the load on the wastewater treatment system.
[0087] According to this embodiment, since the outflow of the adsorbent 46 is prevented by the frit 45, an adsorption column 41 that is easy to transport, store, attach to the waste treatment device 30, and remove from the waste treatment device 30 can be provided.
[0088] As described above, this embodiment has been explained using a waste disposal device 30 for processing the excrement of patients who have been administered rutatera as an example. The waste disposal device 30 can also be used to process the excrement of patients who have been administered radiopharmaceuticals other than rutatera. When processing the excrement of patients who have been administered radiopharmaceuticals other than rutatera, an adsorbent 46 suitable for adsorbing radionuclides contained in the patient's excrement is used.
[0089] The aforementioned administration schedule of four doses at eight-week intervals is the standard schedule when the radiopharmaceutical is Lutatera. When a radiopharmaceutical other than Lutatera is used, the administration schedule specified for that radiopharmaceutical is adopted. For example, with Pulvict (registered trademark), 7.4 GBq of the drug is administered six times at six-week intervals.
[0090] [Embodiment 2] This embodiment relates to an excrement processing device 30 that uses an adsorption column 41 in which multiple types of adsorbents are stacked and arranged. The parts that are common with Embodiment 1 will not be described.
[0091] Figure 6 is a half-cross-sectional view of the adsorption column 41 of Embodiment 2. In addition to the frits 45 fitted to both ends of the column cylinder 42, four more frits 45 are arranged inside the column cylinder 42. The total of six frits 45 may be identical in specifications, but their material, pore size, thickness, and other specifications may differ from one another.
[0092] In this embodiment, the frits 45 fitted to both ends of the column cylinder 42 are described as end frits 451, and the frits 45 positioned between the two end frits 451 are described as intermediate frits 452. The adsorbent material 46 in this embodiment includes two types: a first adsorbent material 461 and a second adsorbent material 462.
[0093] In Figure 6, four intermediate frits 452 are used as partition plates, and the first adsorbent 461 and the second adsorbent 462 are arranged alternately. The first adsorbent 461 and the second adsorbent 462 are adsorbents 46 that have different specifications such as composition or particle size. That is, the adsorption column 41 of this embodiment has a structure in which the first adsorbent 461 and the second adsorbent 462 are alternately stacked in the longitudinal direction of the column cylinder 42.
[0094] For example, by using octadecylsilyl, which has high adsorption performance of 177 Lu but is expensive, as one of the first adsorbent 461 and the second adsorbent 462, and using activated carbon, which has high organic matter adsorption performance and is inexpensive, as the other, an adsorption column 41 with a good balance of price and performance can be realized.
[0095] Let's explain with a specific example. In Figure 6, activated carbon is used as the first adsorbent 461, and octadecylsilyl is used as the second adsorbent 462. By placing octadecylsilyl, which has high adsorption capacity for 177 Lu, near the narrow-diameter section 421, where turbulence is likely to occur due to the narrowing of the fluid, an adsorption column 41 that efficiently brings out the performance of octadecylsilyl can be realized.
[0096] The number of intermediate frits 452 used in a single adsorption column 41 may be three or fewer, or any number of five or more. Figure 6 shows an example in which the frits 45 and adsorbent 46 are arranged symmetrically across the longitudinal center of the adsorption column 41, but the arrangement of the frits 45 and adsorbent 46 does not need to be symmetrical. Three or more types of adsorbent 46 may be used in a single adsorption column 41.
[0097] The type and arrangement of the adsorbent 46 should preferably be determined appropriately based on, for example, the type of radioactive drug and the patient's constitution. Medical professionals such as physicians or clinical laboratory technicians may select an adsorption column 41 from among several types of adsorption columns 41 packed with various combinations of adsorbent 46 that is suitable for removing radioactive substances discharged from the patient.
[0098] An intermediate frit 452 may be sandwiched between layers of adsorbent 46 of the same specifications. The presence of the intermediate frit 452 prevents uneven distribution of the adsorbent 46 due to phenomena such as the sedimentation of relatively small particles during storage.
[0099] According to this embodiment, an adsorption column 41 with a good balance of cost and performance can be provided. According to this embodiment, an excrement processing device 30 can be provided that allows selection of an adsorption column 41 that effectively removes radioactive materials discharged from patients.
[0100] When processing the excrement of patients who have received radiopharmaceuticals other than Lutatera, a combination of adsorbents 46 suitable for adsorbing radionuclides contained in the patient's excrement is used. It is desirable that the combination of adsorbents 46 used in the adsorption column 41 be determined so as to maximize the removal rate of radionuclides contained in the patient's excrement.
[0101] [Embodiment 3] This embodiment relates to an excrement processing device 30 in which a filter 73 is inserted into an adsorption column 41. Parts common to Embodiment 1 will not be described.
[0102] Figure 7 is a half-cross-sectional view of the adsorption column 41 of the third embodiment. The adsorption column 41 of this embodiment has a cylindrical column tube 42 without a constriction, with column caps 43 attached to both ends.
[0103] At each end of the column cylinder 42 are two end frits 451, with a filter 73 sandwiched between them. The end frits 451 sandwiching the filter 73 are thinner on the side closer to the tube mounting port 431.
[0104] The filter 73 is a urethane sponge filter, for example, formed by foaming urethane to create an open-cell urethane foam. The filter 73 may also be a nonwoven fabric filter using polymer fibers such as polypropylene fibers or polyester fibers. The filter 73 may also be a metal mesh filter using metal fibers such as stainless steel wire or aluminum wire.
[0105] By sandwiching the filter 73 between two end frits 451, the filter 73 can be kept in a flat state. Therefore, phenomena such as the filter 73 bending during the assembly process of the adsorption column 41 can be prevented, and liquid that has not passed through the filter 73 can be prevented from entering the adsorbent material 46.
[0106] Figure 7 shows an adsorption column 41 in which two intermediate frits 452 are placed in the middle of 42, and three types of adsorbents 46, a first adsorbent 461, a second adsorbent 462, and a third adsorbent 463, are contained with each intermediate frit 452 as a boundary. The number of intermediate frits 452 and the types of adsorbents 46 used are determined appropriately according to the amount of radioactive material excreted in the patient's urine and the composition of the patient's urine.
[0107] Figure 8 is a graph showing the relationship between the liquid flow rate and flow velocity of the adsorption column 41 in Embodiment 3. The horizontal axis represents the amount of liquid that has passed through the adsorption column 41. The unit of the horizontal axis is grams. The vertical axis represents the liquid flow velocity measured downstream of the pump 56. The unit of the vertical axis is grams / minute.
[0108] The black circles represent data obtained using the adsorption column 41 as explained in Figure 7. The black squares represent data obtained using the adsorption column 41 with the filter 73 removed, as explained in Figure 7.
[0109] The first container 31 contained urine collected from a patient who had received Lutatera and was in isolation. The pumping speed of the pump 56 was set to 12 milliliters per minute. For the filter 73, a 3.5 mm thick Moltofilter (registered trademark) MF-50 manufactured by Inoac Corporation was used. MF-50 is a polyester-based urethane filter.
[0110] Table 2 shows the adsorbent material 46 packed into the adsorption column 41. Note that the lower side of the adsorption column 41 shown in Figure 7 was used as the inlet and the upper side as the outlet.
[0111]
[0112] The flow rate immediately after the start of fluid flow is 12 milliliters per minute, the same as the setting value of the pump 56. As shown in the black square plot, when using the adsorption column 41 without the filter 73, the flow rate drops sharply when the fluid volume is slightly less than 200 milliliters, making it difficult to pass more than 300 milliliters of urine through.
[0113] As shown in the black dot plot, when using the adsorption column 41 with filter 73, the flow rate gradually decreased, and after processing about 2000 grams of urine, the flow rate was about half of the initial rate. The average daily urine volume of a normal adult is about 1.5 liters, or about 1500 grams.
[0114] The reason for the decrease in flow rate is clogging of the adsorbent 46 by solid components such as crystals and precipitates that occur in the urine. The amount and properties of solid components vary greatly from person to person, and even in the same person, they fluctuate depending on their physical condition and diet. Therefore, there is considerable variation in the degree of decrease in flow rate.
[0115] However, as shown in Figure 8, it can be expected that an adsorption column 41 with a filter 73 can process almost a full day's worth of urine from one patient with just one column.
[0116] Next, an overview of the experimental results measuring the removal rate of radionuclides by the waste treatment device 30 of this embodiment will be described. The adsorption column 41 used is the same as the adsorption column 41 described using Figure 7 and Table 2.
[0117] The first container 31 contained 2009 grams of urine collected from a patient who had received Lutatera within 24 hours after administration. The pump 56 was set to a flow rate of 10 grams per minute, and the waste disposal device 30 was operated until the first container 31 was empty. The results of the radioactivity measurement are shown in Table 3.
[0118]
[0119] The amount of radioactivity in the urine after processing refers to the amount of radioactivity in the liquid accumulated in the second container 32. Approximately 80 percent of the radioactivity in the urine was removed by a single processing step. The removed radioactivity was adsorbed onto the adsorption column 41.
[0120] The sum of the radioactivity in the urine after treatment and the radioactivity in the column was 3962 Bq, which is slightly higher than the radioactivity in the urine before treatment. This is due to measurement errors caused by the differences in the geometric shape and dimensions of the sample used for measuring the radioactivity in the urine before and after treatment, and for measuring the radioactivity in the column.
[0121] According to this embodiment, clogging of the adsorbent 46 can be prevented. Therefore, an adsorption column 41 capable of processing a day's worth of urine from an adult can be provided in a single column. As shown in Table 3, a single adsorption column 41 can remove approximately 80 percent of the radioactivity from the urine excreted by a patient in a day.
[0122] Since the adsorption column 41 does not need to be replaced for a full day, the risk of exposure to radiation for medical personnel and others who are responsible for replacing the adsorption column 41 can be reduced.
[0123] Note that the filter 73 on the outlet side is not required. However, by placing filters 73 at both ends of the adsorption column 41, it is possible to provide an adsorption column 41 that is less prone to clogging even if the inlet and outlet are accidentally connected in reverse.
[0124] [Modified Version] Figure 9 is a half-cross-sectional view of the modified adsorption column 41. Parts common to Embodiment 3 will not be explained.
[0125] The adsorption column 41 in this modified example is obtained by adding one filter 73 and one frit 45 to each end of the adsorption column 41 of Embodiment 1, which was described using Figure 5. Similarly, it is also possible to add a filter 73 to the adsorption column 41 of Embodiment 2, which was described using Figure 6.
[0126] [Embodiment 4] This embodiment relates to an excrement processing device 30 in which two adsorption columns 41 are connected in series. The parts that are common with Embodiment 1 will not be described.
[0127] Figure 10 is an explanatory diagram illustrating the configuration of the excrement processing device 30 of Embodiment 4. The excrement processing device 30 of this embodiment is the same as the excrement processing device 30 of Embodiment 1 described using Figure 2, with the addition of one adsorption column 41. An eighth tube 28 is connected between the first adsorption column 41 and the second adsorption column 41. Therefore, the two adsorption columns 41 are connected in series.
[0128] In this embodiment, any of the adsorption columns 41 described using, for example, Figures 5, 6, 7, and 9 may be used as the adsorption column 41. The two adsorption columns 41 may have the same specifications or different specifications. The two adsorption columns 41 may each be filled with different adsorbents 46.
[0129] This section outlines the experimental results of measuring the removal rate of radionuclides by the waste treatment device 30 of this embodiment. The adsorption column 41 used is the same as the adsorption column 41 used in Embodiment 3 when the measurement results in Table 3 were obtained. That is, it is an adsorption column 41 having a filter 73 of uniform thickness as explained using Figure 7, and the filter 73 is a 3.5 mm thick Molt Filter MF-50 manufactured by Inoac Corporation. The packed adsorbent material 46 is the same as that in Table 2.
[0130] The first container 31 contained urine collected from several patients who had received Lutatera, each within 24 hours after administration. The pumping speed of the pump 56 was set to a predetermined value, and the excrement processing device 30 was operated until the first container 31 was empty. The experimental results are shown in Table 4. Of the two adsorption columns 41, the first column represents the upstream adsorption column 41, and the second column represents the downstream adsorption column 41. "N / A (Not Available)" means that measurement data is not available.
[0131]
[0132] Table 4 shows that by connecting two adsorption columns 41 in series, more than 99 percent of the radioactivity in urine can be removed. Most of the radioactivity adsorbed by adsorption column 41 is adsorbed onto the first column located upstream.
[0133] According to this embodiment, it is possible to provide a waste treatment device 30 that reduces the amount of radioactivity contained in the urine of a patient excreted 24 hours after administration of Lutatera to about one-hundredth of the original amount.
[0134] As mentioned above, when medical institutions discharge so-called radioactive wastewater containing radioactive materials, they must either wait for the radioactive dose to decrease to the levels specified in the aforementioned wastewater standards, or dilute it to reduce the radiation level, before discharging it into the sewer system.
[0135] As described in Embodiment 1, the urine of patients who have been administered Lutatera contains a small amount of 177m-Lu, which has a physical half-life of 160.4 days. Since it takes approximately seven half-lives for the amount of radioactivity to decrease to one-hundredth, it takes 1120 days for 177m-Lu to decrease to one-hundredth due to radioactive decay.
[0136] There is no difference in the amount of adsorption by the adsorption column 41 between radioactive isotopes. Therefore, by using the waste treatment device 30 of this embodiment, the period that would take 1120 days if we were to wait for the physical half-life can be reduced to about one day. Consequently, the capacity of the storage tank for radioactive waste liquid can be saved.
[0137] Furthermore, if the storage tank for radioactive waste becomes full, medical institutions will be unable to continue diagnosis and treatment using radionuclides. By using the waste treatment device 30 of this embodiment, it is possible to prevent the storage tank for radioactive waste from becoming full and to prevent delays in patient diagnosis and treatment. Therefore, by using the waste treatment device 30, delays in diagnosis and treatment can be prevented, contributing to the prognosis and healthy lifespan of many patients.
[0138] [Modification 4-1] This modification relates to an excrement processing device 30 that uses an adsorption column 41 without a filter 73 in combination with a pre-filter unit 70. The parts common to Embodiment 4 will not be described.
[0139] Figure 11 is an explanatory diagram illustrating the configuration of the waste disposal device 30 in modified example 4-1. In this modified example, the adsorption column 41 without the filter 73 described in Embodiment 1 and Embodiment 2 is used. A pre-filter unit 70 is connected between the upstream adsorption column 41 and the spiral tube 58.
[0140] Figure 12 is a cross-sectional view of the pre-filter unit 70. The filter 73 and frit 45 are housed inside the filter case 76. The filter case 76 is a hollow, flat plate, with an outlet connection port 761 protruding from the center of one side and an inlet connection port 762 protruding from the center of the other side.
[0141] The outlet connection port 761 has a tapered shape on both its outer and inner surfaces. The outlet connection port 761 has a uniform diameter on its outer surface and an outward-facing tapered shape on its inner surface.
[0142] The frit 45 is positioned on the outlet side connection port 761, and the filter 73 is positioned on the inlet side connection port 762. The combined thickness of the frit 45 and the filter 73 is less than the thickness of the inner surface of the cavity, and there is space between the surface of the frit 45 on the outlet side connection port 761 and the surface of the filter 73 on the inlet side connection port 762.
[0143] As shown in Figure 12, the frit 45 and filter 73 are fixed to the center of the filter case 76 in the thickness direction, and it is desirable that they do not come into close contact with the inner surface on the outlet side connection port 761 side or the inner surface on the inlet side connection port 762 side.
[0144] The liquid flowing in from the inlet port 762 spreads between the inner surface of the filter case 76 and the surface of the filter 73 and passes through the filter 73 and the frit 45. The liquid that has passed through collects between the frit 45 and the inner surface of the filter case 76 towards the outlet port 761 and flows out from the outlet port 761. Therefore, the liquid passes through not only the portion sandwiched between the outlet port 761 and the inlet port 762, but almost the entire surface of the filter 73 and the frit 45.
[0145] According to this modified example, a waste disposal device 30 can be provided in which only the pre-filter unit 70 can be replaced if the filter 73 becomes clogged. A waste disposal device 30 can also be provided in which there is no need to increase the amount of adsorption column 41 used, even in the urine of patients with a large amount of solid components in their urine.
[0146] Three or more adsorption columns 41 may be connected in series. The pre-filter unit 70 may be placed at any location in the pre-column transport path, for example, upstream of the spiral tube 58. However, if it is placed upstream of the spiral tube 58, the pre-filter unit 70 must be treated as infectious waste.
[0147] [Modification 4-2] This modification relates to an excrement processing device 30 that uses adsorption columns 41 without a filter 73 connected in parallel. The parts that are common with Modification 4-1 will not be explained.
[0148] Figure 13 is an explanatory diagram illustrating the configuration of the waste disposal device 30 in modified example 4-2. A pre-filter unit 70 is connected to the upstream side of each of the two adsorption columns 41. The sets of adsorption columns 41 and pre-filter units 70 are connected in parallel. It is preferable that the adsorption columns 41 connected in parallel have the same specifications.
[0149] According to this modified version, even for patients whose urine cannot be processed by a single adsorption column 41 due to reasons such as a large urine volume, a waste disposal device 30 can be provided that does not require the replacement of the pre-filter unit 70 and the adsorption column 41 midway through the process. For example, for patients whose isolation period is expected to be two days, by using the waste disposal device 30 of this modified version, the replacement of the pre-filter unit 70 and the adsorption column 41 is not required until the end of the isolation period.
[0150] Therefore, we can provide a waste disposal device 30 that can reduce the workload and radiation exposure of medical personnel.
[0151] Furthermore, three or more sets of pre-filter units 70 and adsorption columns 41 may be connected in parallel. Instead of the combination of pre-filter units 70 and adsorption columns 41, an adsorption column 41 with a built-in filter 73 may be used.
[0152] [Embodiment 5] This embodiment relates to an excrement processing device 30 with three adsorption columns 41 connected together. The parts that are common with Embodiment 1 will not be described.
[0153] Figure 14 is an explanatory diagram illustrating the configuration of the excrement processing device 30 of Embodiment 5. The excrement processing device 30 of this embodiment is the same as the excrement processing device 30 of Embodiment 1 described using Figure 2, but with the addition of two adsorption columns 41. The first adsorption column 41 and the second adsorption column 41 are connected in parallel, and one adsorption column 41 is connected downstream of these two adsorption columns 41.
[0154] In this embodiment, any of the adsorption columns 41 described using, for example, Figures 5, 6, 7, and 9 may be used as the adsorption column 41. It is preferable that the two adsorption columns 41 connected in parallel have the same specifications. The adsorption column 41 connected downstream may have the same specifications as the two adsorption columns 41 connected in parallel, or it may have different specifications.
[0155] This section outlines the experimental results of measuring the removal rate of radionuclides by the waste treatment device 30 of this embodiment. The adsorption column 41 used is the same as the adsorption column 41 used in Embodiment 3 when the measurement results in Table 3 were obtained. That is, it is an adsorption column 41 having a filter 73 of uniform thickness as explained using Figure 7, and the filter 73 is a 3.5 mm thick Molt Filter MF-50 manufactured by Inoac Corporation. The packed adsorbent material 46 is the same as that in Table 2.
[0156] The first container 31 contained urine collected from several patients who had received Lutatera, each within 24 hours of administration. The pump 56 was set to a flow rate of 5 grams per minute, and the excrement processing device 30 was operated until the first container 31 was empty. The experimental results are shown in Table 5.
[0157] Of the three adsorption columns 41, the first and second columns are shown as two adsorption columns 41 connected in parallel. The third column is shown as an adsorption column 41 connected in series downstream.
[0158]
[0159] Table 5 shows that by connecting three adsorption columns 41 in series, more than 99.5 percent of the radioactivity in urine can be removed. Most of the radioactivity adsorbed by the adsorption column 41 is adsorbed onto the first and second columns located upstream.
[0160] According to this embodiment, it is possible to provide a waste treatment device 30 that reduces the amount of radioactivity contained in the urine of a patient excreted 24 hours after administration of Lutatera to about 1 / 200th.
[0161] The technical features (constituent elements) described in each embodiment are combinable with each other, and by combining them, new technical features can be formed. The embodiments disclosed herein should be considered in all respects to be illustrative and not restrictive. The scope of the invention is indicated by the claims, not in the sense described above, and all modifications within the meaning and scope equivalent to the claims are intended to be included.
[0162] The independent and dependent claims described in the claims can be combined with each other in any combination, regardless of the form of reference. Furthermore, while the claims use a multi-claim format in which claims refer to two or more other claims (multi-claim format), this is not the only option. A multi-claim format in which at least one multi-claim is referenced (multi-multi-claim format) is also acceptable.
[0163] 21 First tube 22 Second tube 23 Third tube 24 Fourth tube 25 Fifth tube (post-column transport path) 26 Sixth tube 27 Seventh tube 28 Eighth tube 30 Excrement processing device 31 First container 32 Second container 33 Third container 38 Housing 41 Adsorption column 42 Column cylinder 421 Narrow diameter section 422 Flat section 43 Column cap 431 Tube mounting port 451 End frit 452 Intermediate frit 46 Adsorbent 461 First adsorbent 462 Second adsorbent 463 Third adsorbent 51 Ultraviolet lamp 52 Light-emitting section 53 Light-shielding body 56 Pump (tube pump) 58 Helical tube 61 First valve 62 Second valve 70 Pre-filter unit 73 Filter 76 Filter case 761 Outlet side connection port 762 Inlet connection port
Claims
1. An excrement processing device comprising: a first container for containing the excrement of a patient who has been administered a radiopharmaceutical; an adsorption column for adsorbing radioactive substances contained in the excrement; a pre-column transport path for transporting the excrement from the first container to the adsorption column; an ultraviolet lamp for irradiating the pre-column transport path with ultraviolet light; a post-column transport path for transporting the excrement from the adsorption column to a second container; and a tube pump positioned in the middle of the post-column transport path.
2. The excrement processing apparatus according to claim 1, wherein the excrement is the patient's urine.
3. The excrement processing apparatus according to claim 2, wherein the excrement includes the feces of the patient.
4. The excrement processing apparatus according to claim 1, wherein the ultraviolet lamp comprises a rod-shaped light-emitting part, and the column pre-transport path is wrapped around the light-emitting part.
5. The waste disposal apparatus according to claim 1, wherein the adsorption column is equipped with a filter on the inlet side, and a plurality of the adsorption columns are connected in series between the pre-column transport path and the post-column transport path.
6. The waste disposal apparatus according to claim 1, wherein the adsorption column is equipped with a filter on the inlet side, and two of the adsorption columns are connected in parallel between the pre-column transport path and the post-column transport path.
7. The waste disposal apparatus according to claim 1, wherein a filter is placed in the middle of the column pretransport path.
8. The excrement processing apparatus according to any one of claims 1 to 7, wherein the adsorption column comprises a cylindrical column tube having a narrow diameter section with a smaller inner diameter than the ends; column caps attached to both ends of the column tube and having tube attachment ports; end frits positioned at both ends of the column tube; and an adsorbent filling the region surrounded by the end frits and the column tube.
9. The waste disposal apparatus according to claim 8, wherein multiple types of adsorbents with different specifications are stacked in the longitudinal direction of the column cylinder.
10. The excrement processing apparatus according to claim 8, wherein the adsorbent comprises a first adsorbent which is activated carbon and a second adsorbent which is different from the first adsorbent, and the first adsorbent and the adsorbent are alternately stacked in the longitudinal direction of the column cylinder, and an intermediate frit is disposed between the first adsorbent and the second adsorbent.
11. An adsorption column comprising: a cylindrical column tube having a narrow diameter section with a smaller inner diameter than the ends; column caps attached to both ends of the column tube and having tube mounting ports; end frits positioned at both ends of the column tube; and an adsorbent filled in the region surrounded by the end frits and the column tube.
12. The adsorption column according to claim 11, wherein the adsorbent comprises a first adsorbent which is activated carbon and a second adsorbent which is different from the first adsorbent, and the first adsorbent and the second adsorbent are alternately stacked in the longitudinal direction of the column tube, and an intermediate frit is disposed between the first adsorbent and the second adsorbent.
